Immune response following fresh arterial homograft replacement for aortoiliac graft infection

European Journal of Vascular and Endovascular Surgery

Volumn 18, Issue 5, 1999, Pages 424-429

  Mirelli, M ^a,b   Stella, A ^a   Faggioli, G L ^a   Scolari, M P ^a   Iannelli, S ^a   Freyrie, A ^a   Buscaroli, A ^a   De Santis, L ^a   Resta, F ^a   Bonomini, V ^a   D'Addato, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Cattedra di Chirurgia Vascolare   (Italy)

Author keywords

Arterial; Graft; Homograft; Immunologic; Infection

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN; HLA ANTIBODY; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ALLOGRAFT; ANTIBODY PRODUCTION; ARTERY DISEASE; ARTERY GRAFT; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; GRAFT INFECTION; GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE SUBPOPULATION; MALE; PRIORITY JOURNAL;

EID: 0033231344     PISSN: 10785884     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejvs.1999.0936     Document Type: Article

References (43)

1. Bahnini A., Ruotolo C., Koskas F., Kieffer E. In situ fresh allograft replacement of an infected aortic prosthetic graft: eighteen month follow-up. J Vasc Surg. 14:1991;98-102.
2. Bahnini A., Plissonier D., Koskas F., Kieffer E. Traitement des infections artérielles par allogreffe artérielle in situ. In: Kieffer E, ed. Le Remplacement Artériel: Principes et Applications. Paris: AERCV. 1992;209-219.
3. Kieffer E., Bahnini A., Koskas F et al. In situ allograft replacement of infected infrarenal aortic prosthetic grafts: results in 43 patients. J Vasc Surg. 17:1993;349-356.
4. Vogt P.R., von Segesser L.K., Goffin Y et al. Eradication of aortic infections with the use of cryopreserved arterial homografts. Ann Thorac Surg. 62:1996;640-645.
5. Szilalagyi D.E., Donald R.T., Smith RF et al. Biologic fate of human arterial homografts. Arch Surg. 75:1957;506-529.
6. Szilagyi De, Rodriguez F.J., Smith R.F., Elliot J.P. Late fate of arterial allografts: observations 6 to 15 years after implantation. Arch Surg. 101:1970;721-733.
7. Koskas F., Plissonier D., Bahnini A., Ruotolo C., Kieffer E. In situ arterial allografting for aortoiliac graft infection: a 6-years experience. Cardiovasc Surg. 4:1996;495-499.
8. Ruotolo C., Plissonier D., Bahnini A., Koskas F., Kieffer E. In situ arterial allografts: a new treatment for aortic prosthetic infection. Eur J Endovasc Surg. 14 (Suppl. A):1997;102-107.
9. Mennander A., Tiisala S., Halttunen J et al. Chronic rejection in rat aortic allografts: An experimental model for transplant arteriosclerosis. Arterioscler Thromb. 11:1991;671-680.
10. Plissonier D., Levy B., Salzmann JL et al. Allograft-induced arterial wall injury and response in normotensive and hypertensive rats. Arterioscler Thromb. 11:1991;1690-1699.
11. Plissonier D., Nochy D., Poncet P et al. Sequential immunologic targeting of chronic experimental arterial allograft. Transplantation. 60:1995;414-424.
12. Mirelli M., Nanni-Costa A., Scolari MP et al. Mismatch-specific anti-HLA antibody production following aorta transplants. Transpl Int. 11 (Suppl. 1):1998;S444-S447.
13. Shaddy R.E., Hunter D.D., Osborn KA et al. Prospective analysis of HLA immunogenicity of cryopreserved valved allografts used in pediatric heart surgery. Circulation. 5:1996;1063-1067.
14. Rajani B., Mee R.B., Ratliff N. Evidence for rejection of homograft cardiac valves in infants. J Thorac Cardiovasc Surg. 1:1998;111-117.
15. den Hamer L., Hepkema B., Prop J., Elzenga N., Ebels T. HLA antibodies specific for cryopreserved heart valve homografts in children. J Thorac Cardiovasc Surg. 2:1997;417-419.
16. Hoekstra F., Knoop C., Vaesse L et al. Donor-specific cellular immune response against human cardiac valve. J Thorac Cardiovasc Surg. 3:1996;281-286.
17. Hogan P., Duplock L., Green M et al. Human aortic valve allografts elicit a donor-specific immune response. J Thorac Cardiovasc Surg. 5:1995;1260-1267.
18. Smith J.D., Ogino H., Hunt D et al. Humoral immune response to human valve homografts. Ann Thorac Surg. 60:1995;S127-S130.
19. NIH Staff, Transplantation and immunology branch: NIH Lymphocyte microtoxicity technique. In: Ray JG, Hare DB, Pedersen PD, Kaynohe DE, eds. Manual of Tissue Typing Technique. Bethesda National Institute of Health. 1974;20.
20. Olerup O., Aldener A., Fogdell A. HLA-DQB1and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Tissue Antigens. 41:1993;119-134.
21. Olerup O., Zetterquist H. HLA-DR by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantations. Tissue Antigens. 39:1992;225-235.
22. Jackson A. Basic phenotyping of lymphocytes: Selection and testing of reagents and interpretation of data. Clin Immunol Newlett. 10:1990;43-55.
23. Jackson A., Warner N. Preparation, staining and analysis by flow cytometry of peripheral blood leukocytes. In: Rose N, Friedman H, Fahey J, eds. Manual of Clinical Laboratory Immunology 3rd ed. Washington DC: American Society for Microbiology. 1986;226-235.
24. Pouletty P., Ferrone S., Amesland F. Summary report from the 1st International Workshop on soluble HLA antigens. Paris, August 1992. Tissue Antigens. 42:1993;45-54.
25. Grumet F.C., Buelow R., Grosse-Wilade H et al. Report of The Second International Soluble HLA (sHLA) Workshop. Human Immunol. 40:1994;153-165.
26. Pouletty C., Mercier I., Glanville L et al. Typing of a panel soluble HLA class I antigens by ELISA. Human Immunol. 40:1994;218-227.
27. Buelow R., Mercier I., Glanville L et al. Detection of panel reactive antibodies by ELISA or lymphocytotoxicity: Results of a blinded controlled multicenter study. Human Immunol. 44:1995;1-11.
28. Ting A. The lymphocytotoxic cross-match test in clinical renal transplantation. Transplantation. 35:1983;403-407.
29. Muirhead K.A., Horan P.K., Poste G. Flow-cytometry: present and future. Biotechnology. 3:1985;337-356.
30. Garovoy M.R., Rheinschmidt M.A., Bigos M et al. Flow cytometry analysis. A high technology cross-match technique facilitating transplantation. Transplant Proc. 15:1983;1939-1944.
31. Stefoni S., Nanni-Costa A., Buscaroli A et al. Validity of flow cytometry for cross-match evaluation in clinical renal transplantation. Nephron. 57:1991;268-272.
32. Siegel, S, Non-parametric Statistics for the Behavioral Sciences. New York (NY): McGraw-Hill, 1956.
33. Norusis M.J., SPSS Inc. SPSS/PC+4.0 Base, Statistics and Advanced Statistics Manuals for the IBM PC/XT/AT and PS/2. Chicago (IL): Spss Inc. 1990.
34. Nanni-Costa A., Scolari M.P., Iannelli S et al. The presence of post-transplant HLA-specific IgG antibodies detected by ELISA correlates with specific rejection pathologies. Transplantation. 63:1997;167-169.
35. Smith J.D., Danskine A.J., Rose M.L., Yacoub M.H. Specificity of lymphocytotoxic antibodies formed after cardiac transplantation and correlation with rejection episode. Transplantation. 6:1992;1358-1362.
36. Rose E.A., Craig R.S., Petrossian G.A., Barr M.L., Reemtsma K. Humoral immune response after cardiac transplantation: correlation with fatal rejection and graft atherosclerosis. Surgery. 106:1989;203-208.
37. Suciu-Foca N., Reed E., Marboe C et al. The role of anti-HLA antibodies in heart transplantation. Transplantation. 51:1991;716-724.
38. Callow A.D. Arterial homografts. Eur J Vasc Endovasc Surg. 12:1996;272-281.
39. Salomon R.N., Friedman G.B., Callow A.D., Payne D.D., Libby P. Cryopreserved homografts contain viable muscle cells capable of expressing transplantation antigens. J Thorac Cardiovasc Surg. 106:1993;1173-1180.
40. Carpenter J.P., Tomaszewsky J.E. Human saphenous vein allograft bypass grafts: immune response. J Vasc Surg. 3:1998;492-499.
41. Nardo B., Bellusci R., Badiali De Giorgi L et al. Ultrastructural aspects of the iliac arteries of multiorgan donor preserved in University of Wisconsin solution for 48 hours. Transpl Proc. 5:1992;2077-2078.
42. Yacoub M., Nasser N.H., Rasmi RH et al. Surgery for acquired heart disease: fourteen-year experience with homovital homografts for aortic valve replacement. J Thorac Cardiovasc Surg. 110:1995;186-194.
43. Mirelli, M, Stella, A, Faggioli, GL et al, Le traitement immunosuppresseur chez les malades soumis à une allogreffe vasculaire pour infection prothétique est-il justifié? Résultats préliminaires. Deuxième Réunion de lAssociation pour la transplantation vasculaire. Paris, 25 January, 1997, 39-40.